| Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. | |
| | |
MedLine Citation:
|
PMID: 11481696 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Dyskinesia is a frequent and disabling side effect in patients with Parkinson's disease treated with chronic dopa-therapy. Preclinical data in the 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (MPTP) monkey suggest that alpha-2 antagonists may reduce dihydroxyphenylalanine (L-DOPA)-induced dyskinesia. We assessed, in a pilot randomised placebo-controlled study, the effects of single oral doses (10 mg, 20 mg, and 40 mg) of idazoxan, an alpha-2 antagonist, on motor parkinsonian disability and L-DOPA-induced dyskinesia following an acute oral challenge of L-DOPA in 18 patients with Parkinson's disease. The severity of L-DOPA-induced dyskinesia improved after 20 mg idazoxan pretreatment, while there was no concommittant deterioration in the antiparkinsonian response to L-DOPA. These results suggest that blocking alpha-2 receptors in patients with Parkinson's disease might improve L-DOPA-induced dyskinesia without the cost of a return of parkinsonian symptomatology. Further studies are required to assess whether this property could have potential therapeutic applications in the long-term management of dyskinetic patients with Parkinson's disease. |
| | |
Authors:
|
O Rascol; I Arnulf; H Peyro-Saint Paul; C Brefel-Courbon; M Vidailhet; C Thalamas; A M Bonnet; S Descombes; B Bejjani; N Fabre; J L Montastruc; Y Agid |
Related Documents
:
|
15927256 - Pathological synaptic plasticity in the striatum: implications for parkinson's disease. 11898536 - Parkinson's disease: surgical options. 18660736 - Early diagnosis of parkinson's disease and initiation of treatment. 14552886 - Increased striatal pre-proenkephalin b expression is associated with dyskinesia in park... 10380386 - Persistence of self in advanced alzheimer's disease. 21476446 - Does mosquito control have an effect on mosquito-borne disease? the case of ross river ... |
Publication Detail:
|
Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Movement disorders : official journal of the Movement Disorder Society Volume: 16 ISSN: 0885-3185 ISO Abbreviation: Mov. Disord. Publication Date: 2001 Jul |
Date Detail:
|
Created Date: 2001-08-01 Completed Date: 2001-10-18 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8610688 Medline TA: Mov Disord Country: United States |
Other Details:
|
Languages: eng Pagination: 708-13 Citation Subset: IM |
Copyright Information:
|
Copyright 2001 Movement Disorder Society. |
Affiliation:
|
Department of Clinical Pharmacology, Clinical Investigation Centre and INSERM U455, University Hospital, Toulouse, France. rascol@cict.fr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adrenergic alpha-Antagonists / adverse effects, therapeutic use* Aged Antiparkinson Agents / adverse effects*, therapeutic use Dose-Response Relationship, Drug Dyskinesia, Drug-Induced / drug therapy* Female Humans Idazoxan / adverse effects, therapeutic use* Levodopa / adverse effects*, therapeutic use Male Middle Aged Neurologic Examination / drug effects Parkinson Disease / drug therapy* Pilot Projects |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic alpha-Antagonists; 0/Antiparkinson Agents; 0/Levodopa; 79944-58-4/Idazoxan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Genetic polymorphisms of superoxide dismutase in Parkinson's disease.
Next Document: Cervical dystonia in monozygotic twins: case report and review of the literature.